194 related articles for article (PubMed ID: 38159532)
1. Combination therapy with oral antiviral and anti-inflammatory drugs improves the efficacy of delayed treatment in a COVID-19 hamster model.
Sasaki M; Sugi T; Iida S; Hirata Y; Kusakabe S; Konishi K; Itakura Y; Tabata K; Kishimoto M; Kobayashi H; Ariizumi T; Intaruck K; Nobori H; Toba S; Sato A; Matsuno K; Yamagishi J; Suzuki T; Hall WW; Orba Y; Sawa H
EBioMedicine; 2024 Jan; 99():104950. PubMed ID: 38159532
[TBL] [Abstract][Full Text] [Related]
2. Beneficial effect of combinational methylprednisolone and remdesivir in hamster model of SARS-CoV-2 infection.
Ye ZW; Yuan S; Chan JF; Zhang AJ; Yu CY; Ong CP; Yang D; Chan CC; Tang K; Cao J; Poon VK; Chan CC; Cai JP; Chu H; Yuen KY; Jin DY
Emerg Microbes Infect; 2021 Dec; 10(1):291-304. PubMed ID: 33538646
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of ensitrelvir against SARS-CoV-2 in a delayed-treatment mouse model.
Nobori H; Fukao K; Kuroda T; Anan N; Tashima R; Nakashima M; Noda S; Tajiri M; Torii M; Toba S; Uemura K; Sanaki T; Shishido T; Tachibana Y; Kato T
J Antimicrob Chemother; 2022 Oct; 77(11):2984-2991. PubMed ID: 35914182
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo characterization of SARS-CoV-2 resistance to ensitrelvir.
Kiso M; Yamayoshi S; Iida S; Furusawa Y; Hirata Y; Uraki R; Imai M; Suzuki T; Kawaoka Y
Nat Commun; 2023 Jul; 14(1):4231. PubMed ID: 37454219
[TBL] [Abstract][Full Text] [Related]
5. S-217622, a SARS-CoV-2 main protease inhibitor, decreases viral load and ameliorates COVID-19 severity in hamsters.
Sasaki M; Tabata K; Kishimoto M; Itakura Y; Kobayashi H; Ariizumi T; Uemura K; Toba S; Kusakabe S; Maruyama Y; Iida S; Nakajima N; Suzuki T; Yoshida S; Nobori H; Sanaki T; Kato T; Shishido T; Hall WW; Orba Y; Sato A; Sawa H
Sci Transl Med; 2023 Jan; 15(679):eabq4064. PubMed ID: 36327352
[TBL] [Abstract][Full Text] [Related]
6. Efficacy comparison of 3CL protease inhibitors ensitrelvir and nirmatrelvir against SARS-CoV-2 in vitro and in vivo.
Kuroda T; Nobori H; Fukao K; Baba K; Matsumoto K; Yoshida S; Tanaka Y; Watari R; Oka R; Kasai Y; Inoue K; Kawashima S; Shimba A; Hayasaki-Kajiwara Y; Tanimura M; Zhang Q; Tachibana Y; Kato T; Shishido T
J Antimicrob Chemother; 2023 Apr; 78(4):946-952. PubMed ID: 36760083
[TBL] [Abstract][Full Text] [Related]
7. A Vimentin-Targeting Oral Compound with Host-Directed Antiviral and Anti-Inflammatory Actions Addresses Multiple Features of COVID-19 and Related Diseases.
Li Z; Wu J; Zhou J; Yuan B; Chen J; Wu W; Mo L; Qu Z; Zhou F; Dong Y; Huang K; Liu Z; Wang T; Symmes D; Gu J; Sho E; Zhang J; Chen R; Xu Y
mBio; 2021 Oct; 12(5):e0254221. PubMed ID: 34634931
[TBL] [Abstract][Full Text] [Related]
8. Ensitrelvir as a potential treatment for COVID-19.
McCarthy MW
Expert Opin Pharmacother; 2022 Dec; 23(18):1995-1998. PubMed ID: 36350029
[TBL] [Abstract][Full Text] [Related]
9. Co-administration of Favipiravir and the Remdesivir Metabolite GS-441524 Effectively Reduces SARS-CoV-2 Replication in the Lungs of the Syrian Hamster Model.
Chiba S; Kiso M; Nakajima N; Iida S; Maemura T; Kuroda M; Sato Y; Ito M; Okuda M; Yamada S; Iwatsuki-Horimoto K; Watanabe T; Imai M; Armbrust T; Baric RS; Halfmann PJ; Suzuki T; Kawaoka Y
mBio; 2021 Feb; 13(1):e0304421. PubMed ID: 35100870
[TBL] [Abstract][Full Text] [Related]
10. Key benefits of dexamethasone and antibody treatment in COVID-19 hamster models revealed by single-cell transcriptomics.
Wyler E; Adler JM; Eschke K; Teixeira Alves G; Peidli S; Pott F; Kazmierski J; Michalick L; Kershaw O; Bushe J; Andreotti S; Pennitz P; Abdelgawad A; Postmus D; Goffinet C; Kreye J; Reincke SM; Prüss H; Blüthgen N; Gruber AD; Kuebler WM; Witzenrath M; Landthaler M; Nouailles G; Trimpert J
Mol Ther; 2022 May; 30(5):1952-1965. PubMed ID: 35339689
[TBL] [Abstract][Full Text] [Related]
11. An overview of anti-SARS-CoV-2 and anti-inflammatory potential of baicalein and its metabolite baicalin: Insights into molecular mechanisms.
Dinda B; Dinda M; Dinda S; De UC
Eur J Med Chem; 2023 Oct; 258():115629. PubMed ID: 37437351
[TBL] [Abstract][Full Text] [Related]
12. A Novel Glucocorticoid and Androgen Receptor Modulator Reduces Viral Entry and Innate Immune Inflammatory Responses in the Syrian Hamster Model of SARS-CoV-2 Infection.
Rocha SM; Fagre AC; Latham AS; Cummings JE; Aboellail TA; Reigan P; Aldaz DA; McDermott CP; Popichak KA; Kading RC; Schountz T; Theise ND; Slayden RA; Tjalkens RB
Front Immunol; 2022; 13():811430. PubMed ID: 35250984
[TBL] [Abstract][Full Text] [Related]
13. A SCID Mouse Model To Evaluate the Efficacy of Antivirals against SARS-CoV-2 Infection.
Abdelnabi R; Foo CS; Kaptein SJF; Boudewijns R; Vangeel L; De Jonghe S; Jochmans D; Weynand B; Neyts J
J Virol; 2022 Aug; 96(16):e0075822. PubMed ID: 35924921
[TBL] [Abstract][Full Text] [Related]
14. Integrating in silico and in vivo approach for investigating the role of polyherbal oil in prevention and treatment of COVID-19 infection.
Bahl AS; Verma VK; Bhatia J; Arya DS
Chem Biol Interact; 2022 Nov; 367():110179. PubMed ID: 36113631
[TBL] [Abstract][Full Text] [Related]
15. The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model.
Abdelnabi R; Foo CS; Kaptein SJF; Zhang X; Do TND; Langendries L; Vangeel L; Breuer J; Pang J; Williams R; Vergote V; Heylen E; Leyssen P; Dallmeier K; Coelmont L; Chatterjee AK; Mols R; Augustijns P; De Jonghe S; Jochmans D; Weynand B; Neyts J
EBioMedicine; 2021 Oct; 72():103595. PubMed ID: 34571361
[TBL] [Abstract][Full Text] [Related]
16. Antiviral and Anti-Inflammatory Activities of Fluoxetine in a SARS-CoV-2 Infection Mouse Model.
Péricat D; Leon-Icaza SA; Sanchez Rico M; Mühle C; Zoicas I; Schumacher F; Planès R; Mazars R; Gros G; Carpinteiro A; Becker KA; Izopet J; Strub-Wourgaft N; Sjö P; Neyrolles O; Kleuser B; Limosin F; Gulbins E; Kornhuber J; Meunier E; Hoertel N; Cougoule C
Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362409
[TBL] [Abstract][Full Text] [Related]
17. The FDA-Approved Drug Cobicistat Synergizes with Remdesivir To Inhibit SARS-CoV-2 Replication
Shytaj IL; Fares M; Gallucci L; Lucic B; Tolba MM; Zimmermann L; Adler JM; Xing N; Bushe J; Gruber AD; Ambiel I; Taha Ayoub A; Cortese M; Neufeldt CJ; Stolp B; Sobhy MH; Fathy M; Zhao M; Laketa V; Diaz RS; Sutton RE; Chlanda P; Boulant S; Bartenschlager R; Stanifer ML; Fackler OT; Trimpert J; Savarino A; Lusic M
mBio; 2022 Apr; 13(2):e0370521. PubMed ID: 35229634
[TBL] [Abstract][Full Text] [Related]
18. Early Use of Corticosteroid May Prolong SARS-CoV-2 Shedding in Non-Intensive Care Unit Patients with COVID-19 Pneumonia: A Multicenter, Single-Blind, Randomized Control Trial.
Tang X; Feng YM; Ni JX; Zhang JY; Liu LM; Hu K; Wu XZ; Zhang JX; Chen JW; Zhang JC; Su J; Li YL; Zhao Y; Xie J; Ding Z; He XL; Wang W; Jin RH; Shi HZ; Sun B
Respiration; 2021; 100(2):116-126. PubMed ID: 33486496
[TBL] [Abstract][Full Text] [Related]
19. Antiviral activity of oleandrin and a defined extract of Nerium oleander against SARS-CoV-2.
Plante KS; Dwivedi V; Plante JA; Fernandez D; Mirchandani D; Bopp N; Aguilar PV; Park JG; Tamayo PP; Delgado J; Shivanna V; Torrelles JB; Martinez-Sobrido L; Matos R; Weaver SC; Sastry KJ; Newman RA
Biomed Pharmacother; 2021 Jun; 138():111457. PubMed ID: 33721754
[TBL] [Abstract][Full Text] [Related]
20. Ensitrelvir is effective against SARS-CoV-2 3CL protease mutants circulating globally.
Kawashima S; Matsui Y; Adachi T; Morikawa Y; Inoue K; Takebayashi S; Nobori H; Rokushima M; Tachibana Y; Kato T
Biochem Biophys Res Commun; 2023 Feb; 645():132-136. PubMed ID: 36689809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
